Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), S. Stowasser (Ingelheim am Rhein, Germany), C. Coeck (Brussels, Belgium), R. Goeldner (Biberach, Germany), E. Clerisme-Beaty (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America). Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial. 1881

Member's Comments

No comment yet.

Related content which might interest you: Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Yoga in patients with fibrosing interstitial lung diseases – a feasibility trial Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Prognostic significance of pathologically proven chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs): single center retrospective cohort Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021